Statistics
death
DISEASE, EVENT
Progression-free survival (PFS) was calculated both from time of first 131-I-omburtamab injection and from time of relapse pre-cRIT to progression, relapse, or death. Overall survival (OS) was calculated from time of first 131-I-omburtamab injection and time of pre-cRIT relapse until death. Extent of disease at cRIT initiation (no evidence of radiologic and cytologic disease [NED] v measurable disease [MD]) along with bridging therapies were evaluated as predictors of PFS and OS by Kaplan–Meier analysis with log-rank tests. Median follow-up was calculated using reverse Kaplan–Meier analysis with death as a censoring event. Time-to-event analyses were stratified by primary histology. Two-sided 